BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Taspoglutide: Completed Phase III enrollment

Roche completed enrollment of 990 patients with Type II diabetes mellitus inadequately controlled with metformin plus sulphonylurea in the open-label, international Phase III T-emerge 5 trial comparing taspoglutide vs. Lanthus insulin glargine. Patients are receiving 10 mg taspoglutide once weekly or 10 mg once weekly for...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >